Outpatient parenteral antimicrobial therapy (OPAT) has become a wide-spread practice in the United States. The growth of the OPAT market has been driven by its potential to reduce healthcare costs, improve conven-ience for patients and decrease the risk of complications due to hospitalization. Patients with infections requiring often prolonged treatment with intravenous antibiotics and having a relatively low risk of developing fulmi-nant disease are the best candidates for receiving OPAT.
This report provides insight into the management of hospitalized antibiotic-treated patients after discharge and in the outpatient setting, with an emphasis on OPAT treatment. Through market research with infectious diseases specialists, the report analyzes the post-hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically-important pathogens, including MRSA, and identifies factors that drive and constrain physician prescribing of key OPAT therapies. The report will also explore the impact of the emerging long-acting glycolipopeptides on OPAT treatment and hospitalization decisions.

Questions Answered in This Report:

  • - Which patient populations are suitable for OPAT therapy after dis-charge? What are the sites of OPAT administration and reasons for treatment switching and discontinuation.

  • - How do physicians make OPAT treatment choices for patients with a variety of infections, including MRSA and Gram-negative infections. What drives OPAT initiation and what are the preferred therapies?

  • - Which drug attributes influence physicians’ current and future pre-scribing? What are the strengths and drawbacks of current OPAT therapies? Which drug attributes are valued for the outpatient setting?

  • - What is the level of ID physicians’ receptivity to emerging therapies for use in OPAT and in the outpatient setting. How do physicians per-ceive the competitive potential of long-acting glycolipopeptides — Durata’s dalbavancin and The Medicines Company’s oritavancin?


Sample Frame & Methodology:

- ~100 infectious diseases specialists complete a 45-minute online quanti-tative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

- Be board-certified in infectious diseases and affiliated with a hospital

- Have been in practice a minimum of 2 years and a maximum of 30 years

- At least 20 percent of practice in the hospital, inpatient setting

- Have prescribed OPAT to a minimum of 10 patients during the previ-ous month

Key Drugs Covered:

- Cubicin (daptomycin), Zyvox (linezolid), Tygacil (tigecycline), Invanz (ertapenem), vancomycin (generics), Merrem (meropenem), Zosyn (piperacillin/tazobactam), Teflaro (ceftaroline), Vibativ (telavancin), Doribax (doripenem), dalbavancin, oritavancin and tedizolid.

Key Companies Mentioned:

- AstraZeneca, Cubist, Durata, Forest Laboratories, Johnson & Johnson/Janssen, Merck, Pfizer and The Medicines Company


- Final report in Powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions

Related Reports:

- DecisionBase®: Gram-Negative Infections

- DecisionBase®: MRSA and Complicated Skin and Skin Structure Infec-tions

- Pharmacor®: Hospital-Treated Gram-Negative Infections

- Pharmacor®: Hospital-Treated Infections

- Physician and Payer Forum® (U.S.): Gram-Negative Infections

- Physician and Payer Forum® (U.S.): MRSA Infections

- Physician and Payer Forum® (China): Hospital-Treated Infections

- TreatmentTrends® (US): MRSA Infections

- TreatmentTrends® (EU): Gram-Negative Infections